INTERLACE Study: Real-world Data for Germany Based on a Case Series of Patients with Locally Advanced Cervical Cancer

Primary chemoradiotherapy is the established and standard treatment for locally advanced cervical cancer. The INTERLACE study investigated the impact of adding induction chemotherapy with six cycles of carboplatin AUC2 and paclitaxel 80 mg/m ² weekly prior to chemoradiotherapy on recurrence-free and overall survival. However, adaptation with adoption into routine clinical practice in Germany has been rather cautious.

Patients treated according to the INTERLACE scheme at the University Medical Center Hamburg-Eppendorf between October 2023 and December 2024 were evaluated and described.

Seven patients with advanced cervical cancer (ECOG 0-1, median age 37 years, 43% FIGO stage IB1/2) treated with the INTERLACE regimen were identified during the study period. All patients received six cycles of the planned induction chemotherapy. The median time between completion of chemotherapy and the start of radiotherapy was 10 days, with the total duration of treatment varying between 43 and 63 days. All patients were able to complete radiotherapy using tele- and brachytherapy. 43% received all 5-6 cycles of cisplatin, 86% received at least four cycles of cisplatin simultaneously with radiotherapy. There were various reasons for discontinuing concomitant chemotherapy (1 hematological, 3 non-hematological).